TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY

T. Facon, S. K. Kumar, T. Plesner, P. Moreau, N. Bahlis, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. P. Venner, K. Weisel, J. R. Mace, N. Raje, M. Tiab, M. Macro, L. Frenzel, X. Leleu, H. Pei, F. Borgsten, S. Z. Usmani

Research output: Contribution to journalConference abstract in journalResearchpeer-review

Original languageEnglish
Article numberP936
JournalHemaSphere
Volume6
Issue numberSuppl. 3
Pages (from-to)826-827
ISSN2572-9241
DOIs
Publication statusPublished - 2022
EventEHA 2022 Hybrid Congress - Vienna, Austria
Duration: 9. Jun 202212. Jun 2022

Conference

ConferenceEHA 2022 Hybrid Congress
Country/TerritoryAustria
CityVienna
Period09/06/202212/06/2022

Cite this